Evidence map›Paper›PMID 33495408›Full record

ArticleAging2021

ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.

Meng Zheng, Yuchun Niu, Junguo Bu, Shumei Liang, Zhilin Zhang, Jianhua Liu, Linlang Guo, Zhihua Zhang, Qiongyao Wang

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer.Journal of experimental & clinical cancer research : CR · 2025
    Article
  8. Review
  9. Review
  10. Unsupervised cell line embedding using pairwise drug response correlation.Computational and structural biotechnology journal · 2025
    Article
  11. Review
  12. The emerging role of CARM1 in cancer.Cellular oncology (Dordrecht, Netherlands) · 2024
    Review
  13. Small Cell Lung Cancer-An Update on Chemotherapy Resistance.Current treatment options in oncology · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Meng ZhengDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yuchun NiuDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Junguo BuDepartment of Radiotherapy, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Shumei LiangDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhilin ZhangDepartment of Radiotherapy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Jianhua LiuDepartment of Respiratory Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Linlang GuoDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhihua ZhangDepartment of Respiratory Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Qiongyao WangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Hebei North University · CNSouthern Medical University · CNZhujiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial splicing regulatory protein 1 (ESRP1) is an RNA-binding protein that regulates alternative splicing of mRNA. ESRP1 plays an important role in chemoresistance of various cancers, including breast cancer, colon cancer and non-small cell lung cancer. However, the role of ESRP1 and its mechanism in small cell lung cancer (SCLC) chemoresistance remains unclear. In this study, we found that ESRP1 is significantly downregulated in SCLC chemo-resistant cells compared with chemo-sensitive cells. Moreover, the expression of ESRP1 was significantly lower in SCLC tissues than that in normal adjacent tissues and positively correlated with overall survival. Overexpression of ESRP1 increased SCLC chemosensitivity, and induced cell apoptosis and cell cycle arrest, whereas knockdown of ESRP1 induced the opposite effects. ESRP1 could inhibit the growth of SCLC

Indexed as

Alternative SplicingAnimalsAntineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationCisplatinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionEtoposideFemaleGene Expression ProfilingGene Knockdown TechniquesHumansLung NeoplasmsAntineoplastic AgentsCisplatincoactivator-associated arginine methyltransferase 1ESRP1 protein, humanEtoposideProtein-Arginine N-MethyltransferasesRNA-Binding ProteinsRNA, MessengerSmad7 ProteinTransforming Growth Factor betaCARM1chemoresistanceESRP1small cell lung cancerTGF-β/Smad pathway

Identifiers

PMID33495408
PMCPMC7906186
OpenAlexW3125133663

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.